文献速递类风湿关节炎

调节性嗜酸性粒细胞诱导实验性关节炎缓解并在人类类风湿关节炎缓解期出现

Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2020-11-04

该研究将卵清蛋白诱导的嗜酸性哮喘与K/BxN血清诱导的小鼠关节炎结合,发现哮喘诱导的嗜酸性粒细胞可促使关节炎缓解并保护关节组织,其机制涉及肺ILC2释放IL-5系统性上调后关节内调节性嗜酸性粒细胞(rEos)扩增。在人类RA中,rEos存在于缓解期滑膜而非活动期,且合并哮喘的RA患者接受美泊利单抗(抗IL-5抗体)治疗后关节炎复发。

要点

  • 嗜酸性哮喘可诱导小鼠关节炎缓解并保护关节组织。
  • 关节内rEos经肺ILC2-IL-5轴扩增,清除嗜酸性粒细胞则消除有益效应。
  • RA缓解期滑膜存在rEos,美泊利单抗治疗可使合并哮喘的RA患者关节炎复发。

核心结论

  • 嗜酸性粒细胞的一个亚群具有促炎症消退特征,可刺激关节炎缓解。

研究设计与样本

  • 研究采用卵清蛋白诱导的嗜酸性哮喘联合K/BxN血清诱导的小鼠关节炎模型,并通过scRNA-seq比较肺与滑膜嗜酸性粒细胞亚群。
  • 研究使用IL-25和IL-33质粒流体动力学注射、IL-5报告小鼠及抗IL-5抗体治疗探究ILC2-IL-5轴的作用。
  • 在RA患者中检测外周血和滑膜组织中的嗜酸性粒细胞亚群,并监测合并哮喘的RA患者在接受美泊利单抗治疗前后的疾病活动度。

主要发现

  • 诱导嗜酸性哮喘导致小鼠关节炎缓解并保护关节组织。
  • scRNA-seq揭示关节中存在特定的调节性嗜酸性粒细胞(rEos)亚群,与肺部炎症性嗜酸性粒细胞不同。
  • 滑膜rEos在肺ILC2释放的IL-5系统性上调后扩增,清除嗜酸性粒细胞则消除哮喘对关节炎的有益效应。
  • rEos存在于RA缓解期患者滑膜中,但活动期不存在。
  • 合并哮喘的RA患者接受美泊利单抗治疗后出现关节炎复发。

临床怎么用

  • 在RA患者中,尤其合并哮喘者,使用抗IL-5抗体(如美泊利单抗)需警惕关节炎复发的可能。
  • rEos的存在可能与RA缓解状态相关,提示嗜酸性粒细胞亚群可作为疾病活动度的潜在生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Eosinophils possess pro-inflammatory functions in asthma. However, our recent studies have suggested that innate lymphoid cells type 2 (ILC2s) and eosinophils have proresolving properties in rheumatoid arthritis (RA). Nothing is known yet about the mechanisms determining the double-edged role of eosinophils. Therefore, we investigated whether asthma, a paradigm eosinophilic disease, can elicit resolution of chronic arthritis. METHODS: Ovalbumin-triggered eosinophilic asthma was combined with K/BxN serum-induced arthritis, where lung and synovial eosinophil subsets were compared by single-cell RNA sequencing (scRNA-seq). To investigate the involvement of the ILC2-interleukin-5 (IL-5) axis, hydrodynamic injection (HDI) of IL-25 and IL-33 plasmids, IL-5 reporter mice and anti-IL-5 antibody treatment were used. In patients with RA, the presence of distinct eosinophil subsets was examined in peripheral blood and synovial tissue. Disease activity of patients with RA with concomitant asthma was monitored before and after mepolizumab (anti-IL-5 antibody) therapy. RESULTS: The induction of eosinophilic asthma caused resolution of murine arthritis and joint tissue protection. ScRNA-seq revealed a specific subset of regulatory eosinophils (rEos) in the joints, distinct from inflammatory eosinophils in the lungs. Mechanistically, synovial rEos expanded on systemic upregulation of IL-5 released by lung ILC2s. Eosinophil depletion abolished the beneficial effect of asthma on arthritis. rEos were consistently present in the synovium of patients with RA in remission, but not in active stage. Remarkably, in patients with RA with concomitant asthma, mepolizumab treatment induced relapse of arthritis. CONCLUSION: These findings point to a hitherto undiscovered proresolving signature in an eosinophil subset that stimulates arthritis resolution.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Andreev D, Liu M, Kachler K, et al. Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis. Ann Rheum Dis. 2020. PMID: 33148700. doi:10.1136/annrheumdis-2020-218902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。